CTLA4 and neoplasm: Mice that rejected Y1.7AI or Y1.7LI tumors upon neoAg SLP vax or anti-CTLA-4 were rechallenged in the absence of additional treatment with the same tumor lines 60+ days after rejection of the primary tumors.